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Interleukin-1 Mediates Neuroinflammatory Changes Associated
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Background—-Systemic inflammation contributes to brain pathology in cerebrovascular disease through mechanisms that are
poorly understood.
Methods and Results—-Here we show that atherosclerosis, a major systemic inflammatory disease, is associated with severe cere-
brovascular inflammation inmice and that this effect ismediated by the proinflammatory cytokine interleukin-1 (IL-1). Apolipoprotein
E–deficient mice fed Paigen or Western diets develop vascular inflammation, microglial activation, and leukocyte recruitment in the
brain, which are absent in apolipoprotein E–deficient mice crossed with IL-1 type 1 receptor–deficient mice. Systemic neutralization
of IL-1β with an anti–IL-1β antibody reversed aortic plaque formation (by 34% after a Paigen and 45% after a Western diet) and re-
duced inflammatory cytokine expression in peripheral organs. Central, lipid accumulation–associated leukocyte infiltration into the
choroid plexus was reversed by IL-1β antibody administration. Animals fed a Western diet showed 57% lower vascular inflammation
in the brain than that of mice fed a Paigen diet, and this was reduced further by 24% after IL-1β antibody administration.
Conclusions—-These results indicate that IL-1 is a key driver of systemically mediated cerebrovascular inflammation and that inter-
ventions against IL-1β could be therapeutically useful in atherosclerosis, dementia, or stroke. ( J AmHeart Assoc. 2012;1:e002006
doi: 10.1161/JAHA.112.002006.)
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I nflammation is a key driver of cardiovascular and cere-brovascular disease, including atherosclerosis, and con-
tributes to diseases such as myocardial infarction, stroke, and
dementia. These diseases share common risk factors, such as
obesity, hypertension, and diabetes,1,2 that are associatedwith
inflammation. In patients, a clear association exists between
cardiovascular risk factors or carotid atherosclerosis and de-
mentia, progression of Alzheimer’s disease, or depression.3–5
Animal studies demonstrate that peripheral inflammatory con-
ditions are associated with increased neuroinflammatory re-
sponses in the brain and enhanced damage in response to
experimentally induced stroke.6–9
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Interleukin (IL)-1 is a key contributor to a diverse range
of diseases, demonstrated by the beneficial effects of block-
ing endogenous IL-1 in experimental models, most commonly
with the IL-1 receptor antagonist (IL-1Ra).10 Evidence indicates
that IL-1 contributes to peripherally induced neuroinflamma-
tory diseases. Mice that lack IL-1 type 1 receptor (IL-1R1),
when subjected to experimental autoimmune encephalomyeli-
tis, show significantly reduced neuroinflammation, as indicated
by a reduction in vascular adhesion molecule (VCAM)-1 and in-
filtrating immune cells.11 IL-1 expression is increased in human
coronary arteries affected by atherosclerosis12,13 and is also
associated with arterial inflammation, oxidative stress, and in-
creased blood pressure.14
In apolipoprotein E–knockout (ApoE−/−) mice fed high-fat
diets, atheroma development is related to the composition of
the diet; a high-fat, high-cholate (Paigen) diet produces the
largest effect.14 Genetic deletion of IL-1R1 in ApoE−/−, Paigen
diet–fed mice (ApoE−/−/IL-1R1−/−) markedly reduces inflam-
matory responses in the periphery.14 Similar results were seen
in Paigen diet–fed ApoE−/− mice treated with a neutralizing
antibody to IL-1β.15 These findings suggest that IL-1 mediates
the effects of high-fat diets on peripheral vascular atheroscle-
rotic pathology.
Our recent studies show increased cerebrovascular and
brain inflammation in ApoE−/− mice fed an atherogenic
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high-fat diet, though the mechanisms of this response are not
known.6 The primary objective of the present study was to test
the hypothesis that the neuroinflammatory responses associ-
ated with atherosclerosis induced by high-fat feeding in sus-
ceptible (ApoE−/−) mice is mediated by IL-1. To address this,
we determined the neuroinflammatory response to fat feeding
in ApoE−/−/IL-1R1−/− mice and the effect of immunoneutral-
ization of IL-1β on peripheral and central pathology in athero-
genic mice.
Methods
Animals
Experimentswere carried out inmale ApoE−/− (JAX 2052, Jack-
son Laboratories, Bar Harbor, Maine, USA) and ApoE−/−/IL-
1R1−/− mice, the latter generated as described previously.14
Both strains were bred in house at the University of Sheffield,
UK, were allowed free access to food and water, and were
maintained under temperature-, humidity-, and light-controlled
conditions. All animal procedures adhered to the UK Animals
(Scientific Procedures) Act (1986).
Ten-week-old mice were fed a control (4.3% fat, 0.02%
cholesterol), Paigen (18.5% fat, 0.9% cholesterol, 0.5% cholate,
0.26% sodium), or Western (21% fat, 0.15% cholesterol, 0.03%
cholate, 0.296% sodium) diet for a period of 8 weeks, as de-
scribed previously.14 Body weight was recorded weekly, and,
as a measure of well-being and overall fitness, voluntary wheel
running activity was assessed. Blood pressures were recorded
weekly by using a Visitech tail cuff system, as previously
described.14 At the end of the experimental period, blood was
taken from the heart, before transcardial perfusion. Brain, liver,
and spleen samples were taken and prepared as described
previously,6,16 and the aortae were fixed and harvested for en
face Oil Red O staining and aortic root analysis.14
Treatment
Mice were dosed with an anti-mouse anti–IL-1β or anti–
cyclosporin A isotype control antibody17,18 according to weight
(10 mg/kg IP).
Cytokine Measurements
Eleven cytokines were measured in plasma (at weeks 0, 4,
and 8), liver homogenates, and spleen homogenates: tumor
necrosis factor-α, RANTES (CCL5), monocyte chemoattrac-
tant protein-1 (CCL2), KC (CXCL1), IL-6, IL-1β, IL-1α, IL-17α,
interferon-γ , granulocyte-colony stimulating factor, and IL-10.
These were measured with appropriate Cytometric Bead Ar-
ray Flex Sets (BD Biosciences, UK) according to the manu-
facturer’s protocol. Protein concentrations were calculated by
bicinchoninic acid assay (Pierce/Thermo Fisher Scientific, UK).
Assessment of Vascular and Microglial Activation
by Immunohistochemistry
Immunohistochemistry for vascular (VCAM) and microglial ion-
ized calcium binding adaptor molecule 1 (Iba1) activation was
performed on free-floating brain sections. Endogenous per-
oxidase activity and blocking treatment were performed as
stated previously. Primary antibody incubation was performed
overnight with goat anti-mouse VCAM-1 1:250 (R&D Systems,
Abingdon, UK) or rabbit anti-Iba1 1:1000 (Wako Chemicals,
Nuss, Germany). Sections were then incubated in appropri-
ate biotinylated secondary antibody for 1 hour (rabbit anti-
goat 1:1000 and goat anti-rabbit 1:750, Vector Laboratories,
UK), followed by Vectastain ABC solution (Vector Laboratories,
UK), before visualization with nickel-enhanced diaminobenzi-
dine (50 mg/mL) (Vector Laboratories, UK). Sections were
mounted onto gelatin-coated slides and dehydrated, and cov-
erslips were applied with Depex (Fisher, UK). Images were
collected on an Axiocam color charge-coupled device cam-
era (Zeiss, Germany) upright microscope with 10× and 20×
objectives and were captured by a Coolsnap ES camera (Pho-
tometrics, Tucson, Arizona, USA) through Axiovision software
(Zeiss, Germany).
Assessment of Leukocyte Recruitment
in the Brain
Double immunofluorescence was performed to detect leuko-
cytes (CD45) and vascular activation (VCAM) on free-floating
brain sections. After blocking in 2% normal donkey serum
(Vector Laboratories, Burlingame, CA), sections were incu-
bated overnight at 4◦C with primary antibodies: rat anti-mouse
CD45 1:200 (Serotec, UK) and goat anti-mouse VCAM-1 1:250
(R&D Systems). The antigens were visualized with the ad-
equate fluorochrome-conjugated (Alexa 594 1:750 or Alexa
488 1:500, Molecular Probes, Eugene, OR) secondary don-
key anti-sera for 2 hours at room temperature. Sections were
mounted onto gelatin-coated slides and coverslipped with Vec-
tashield mounting medium containing diamidinophenylindole
(DAPI, Vector Laboratories, Burlingame, CA).
Images were collected on an Olympus BX51 upright and
captured by a Coolsnap ES camera (Photometrics, UK) through
MetaVue Software (Molecular Devices, UK).
Histology
Oil Red O staining combinedwith CD45 immunohistochemistry
was performed as described earlier.6
Quantitative Analysis
All analyses were performed blinded. VCAM-positive blood
vessels were counted in 3 random fields of view for each
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section (typically 8 to 10) containing rostro-caudal cerebral
cortex. A score for the whole brain was obtained by averaging
individual counts and was expressed as positive blood ves-
sels per square millimeter. Activated microglia were identified
as showing: (1) increased Iba1 immunopositivity, (2) enlarged
or amoeboid cell body, and (3) complete or partial loss of
thin, elongated processes. Round, small Iba1-positive cellswith
leukocyte morphology were not counted. Activated microglia
were counted throughout the striatum and expressed as ac-
tivated microglia per square millimeter. Fluorescently labeled
CD45-positive cells were counted in the caudal choroid plexus
(−1.82 mm from bregma) and the lateral ventricle (−1.58 mm
from bregma). The choroid plexus and ventricular ependyma
were visualized by VCAM immunofluorescence. Data on the
control mice used to evaluate CD45, VCAM, and Iba1 staining
in ApoE−/−/IL-R1−/− have been published previously.6
Statistical Analysis
Normal distribution of experimental data was examined by
Shapiro-Wilk normality test. Only a minority of data sets did
not pass the normality test (see Results), in which cases ap-
propriate nonparametric tests (Mann-Whitney test for 2 groups
and Kruskal-Wallis test followed by Dunn multiple-comparison
test for≥3 groups) alsowere performed.When normality of the
data had been confirmed, comparisons between 2 experimen-
tal groups weremade with unpaired t tests. Data from 4 groups
(ApoE−/−/IL-R1−/− experiment) were analyzed by one-way
analysis of variance (ANOVA), followed by Bonferroni multiple-
comparison post-test with GraphPad Prism 5 software. Two-
way ANOVA was used to determine the overall effect of diet
and IL-1β on the levels of vascular and microglial activation
and recruitment of CD45-positive cells. Body weight changes
were analyzed by repeated-measures ANOVA. Blood pressure
measurements were analyzed by global nonlinear regression
(to fit blood pressure data over a defined period of time for a
group of animals), followed by an F test (GraphPad Prism 5).
Data are presented as mean±SEM. A probability of <5% was
regarded as statistically significant.
Results
Neuroinflammation in Atherosclerotic ApoE−/−
Mice Is Abolished in ApoE−/−/IL-R1−/− Mice
Diet-induced atherosclerosis in ApoE−/− mice was associated
with marked neuroinflammatory responses in the brain, which
were abolished in animals in which the IL-1 receptor was
deleted. Specifically, in ApoE−/−/IL-R1−/− mice fed a Paigen
diet, microglial activation was significantly reduced compared
to ApoE−/− mice fed a Paigen diet and was similar to that of
mice fed a control diet (Figure 1A and 1D). VCAM-1 was upreg-
ulated throughout the brain in ApoE−/− mice fed a Paigen diet,
whereas there was little or no evidence of vascular activation
in ApoE−/−/IL-R1−/− mice fed a Paigen diet, and in these an-
imals vascular activation was comparable to that of mice fed a
control diet and was significantly lower than in ApoE−/− mice
fed a Paigen diet (Figure 1B and 1E). The enhanced leukocyte
accumulation in ApoE−/− mice fed a Paigen diet was reversed
in ApoE−/−/IL-R1−/− mice to levels comparable to the mice
fed a control diet (Figure 1C and 1F). The marked decline in
voluntary physical activity in ApoE−/− mice was also reversed
by genetic deletion of the IL-1 receptor in the ApoE−/−/IL-
1R1−/− mice (Figure 1G).
Neutralization of IL-1β Reduces Atherosclerotic
Lesion Size in ApoE−/− Mice Fed a High-Fat Diet
Peripheral administration of an anti–IL-1β antibody success-
fully neutralized IL-1β (an average 89% reduction in IL-1 con-
centrations) in all organs where IL-1β expression was de-
tectable, regardless of diet (Figure 2).
Lesion coverage in the descending aorta was reduced sig-
nificantly in IL-1β antibody–treated mice fed either a Paigen or
a Western diet, as compared to control mice (by 34% and 45%
respectively; Figure 3A and 3B). Mice treated with IL-1β anti-
body had significantly smaller lesion areas after having been
fed the Paigen diet, as compared to control antibody–treated
mice (Figure 3D). There was no diet-dependent difference in
lesion size or percentage coverage in either the IL-1β or con-
trol antibody treatment groups. Treatment with IL-1β antibody
had no statistically significant effect on systemic blood pres-
sure in mice fed either diet (data and statistical analysis are
not shown).
IL-1 neutralization reversed the weight loss in mice fed a
Paigen diet over the course of the study period (P<0.001),
whereas there was no difference in the body weight of mice
fed a Western diet, with or without intervention (Figure 1).
IL-1β Neutralization Reduces Peripheral
Inflammation
Consistent with the markedly reduced IL-1β levels described
above, IL-1α was also reduced significantly (37%) in the livers
of mice fed the Paigen diet and in the spleens of mice fed the
Western diet (42%; Figure 4), but no significant reduction was
seen in the spleens of mice fed a Paigen diet and in the livers
of mice fed a Western diet. IL-1β neutralization also reduced
hepatic concentrations of CCL2 (33%) in mice fed a Paigen
diet and interleukin-6 (80%) and CXCL1 (79%) levels in spleens
from mice fed a Western diet (Figure 4). No significant differ-
ences were observed in CCL2, interleukin-6, or CXCL1 levels in
other organs in mice fed a Paigen or Western diet. Levels of IL-
17, interferon-γ , IL-10, or tumor necrosis factor-α were mostly
below the detection limit of the assay or the results were incon-
sistent; therefore, no significant effect of IL-1β neutralization
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Figure 1. Vascular activation, microglial activation, and leukocyte accumulation are reduced in ApoE−/−/IL-1R1−/− mice fed a Paigen diet.
Activated microglia as identified by increased Iba1 immunopositivity, thickened processes, and irregular cell bodies were seen in ApoE−/− mice fed
a Paigen diet. Microglial activation was significantly reduced, to control levels, in ApoE−/−/IL-1R1−/− mice fed a Paigen diet (A). Vascular activation
was assessed through the immunostaining of the adhesion molecule VCAM. Atherosclerotic ApoE−/− mice show increased vascular activation,
which is significantly reduced in ApoE−/−/IL-1R1−/− mice fed a Paigen diet (B). Leukocyte accumulation as shown by CD45 immunostaining was
increased in ApoE−/− mice fed a Paigen diet. Leukocyte accumulation was significantly reduced, to control levels, in ApoE−/−/IL-1R1−/− mice fed
a Paigen diet (C). D, Quantification of Iba1-positive microglia. E, Quantification of VCAM-positive blood vessels. F, Quantification of CD45-positive
leukocytes. The “vehicle” data in F were not normally distributed; therefore, in addition to one-way ANOVA (P=0.017) followed by Bonferroni
multiple-comparison post-test, nonparametric Kruskal-Wallis test (P=0.0065) followed by Dunn multiple-comparison test also were performed.
Post-hoc comparisons gave identical results. A through F: n=6–10. G, Voluntary wheel running actogram for ApoE−/− and ApoE−/−/IL-1R1−/−
mice (n=2–3). Error bars represent standard error, *P<0.05. Scale bars: 200 μm (A through C) and 10 μm (inset in C).
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Figure 2. Neutralization of IL-1β in anti–IL-1β antibody–treatedmice. Cytokines weremeasured by Cytometric Bead Array. IL-1β was neutralized
in the livers and spleens of ApoE−/− mice fed a Paigen diet and in the spleens of mice fed a Western diet, as compared with mice treated with
control antibody. Error bars represent standard error, *P<0.05 and **P<0.01 vs ApoE−/− mice treated with a control antibody (n=7–11).
was observed. The lack of statistical significance might be a
result of underpowered analysis in some cases.
IL-1β Neutralization Attenuates Vascular
Activation in ApoE−/− Mice Fed a Western Diet
Microglial and vascular activation have been reported previ-
ously in the brains of atherosclerotic ApoE−/− mice fed a
Paigen diet, but no information is available on mice fed a
Western diet. Mice fed a Paigen diet showed microglial ac-
tivation that was 41% higher than in mice fed a Western diet
(Figure 5). Microglial activation was observed in the cerebral
cortex, striatum, periventricular areas, and meninges, as re-
ported previously.6 The number of activated microglial cells in
mice fed a Paigen or Western diet was not different after IL-1β
neutralization (Figure 5). Mice fed the cholate-free, high-fat,
Western diet showed a 57% reduction in vascular activation
when compared to mice fed a Paigen diet, as indicated by a
lower number of VCAM-positive blood vessels (Figure 6B and
6C). IL-1β neutralization had no significant effect on vascular
activation in ApoE−/− mice fed a Paigen diet, although a trend
toward reduced activation was observed (the lack of statisti-
cal significance might be a result of underpowered analysis).
In contrast, the neutralization of IL-1β significantly reduced
(24%) vascular activation in mice fed a Western diet (Figure 6B
and 6C).
IL-1β Neutralization Attenuates the
Accumulation of CD45+ Leukocytes in ApoE−/−
Mice in the Lateral Ventricle
Diet-dependent leukocyte accumulation was assessed in coro-
nal brain sections and was found to occur in 2 different regions
of the lateral ventricle (Figure 7A and 7D). Mice fed a Paigen
diet showed increased leukocyte accumulation, principally in
an area of the dorsal lateral ventricle between the hippocam-
pus and the thalamus, as previously shown.6 Treatment with
the anti–IL-1β antibody significantly (P<0.05) attenuated the
number of leukocytes accumulating in the dorsal lateral ventri-
cle in response to the Paigen diet (Figure 7A). In contrast, mice
fed a Western diet showed little accumulation of leukocytes in
this region of the lateral ventricle as compared to mice fed the
Paigen diet (Figure 7B). The accumulation of leukocytes was
found to extend ventrally to the choroid plexus of the ventricu-
lar space in mice fed a Paigen diet (Figure 7C), and mice fed a
Western diet also show increased leukocyte infiltration in this
ventral region, though numbers are reduced compared to the
Paigen diet–fed mice (Figure 7D). Overall, the anti–IL-1β anti-
body reduced leukocyte accumulation in the ventral ventricle
independently of diet, as compared to control antibody (P <
0.05, two-way ANOVA).
Atherogenic Diet Results in Lipid Accumulation in
the Brain, and IL-1β Neutralization Reduces
Lipid-Associated Inflammation in the Lateral
Ventricle
We have previously reported that mice fed a Paigen diet
display focal lipid deposition and inflammation in the brain
parenchyma.6 In the present study, the number of focal
pathologies was relatively low in the parenchyma and was
not affected by IL-1β neutralization. However, Oil Red O
staining revealed lipid accumulation in the lateral ventricle
in mice fed a Paigen diet, which was associated with re-
cruitment of CD45-positive cells and microglial activation
(Figure 8A Through 8F). Lipid accumulation and inflamma-
tion were observed in the choroid plexus, the lumen of
the dorsal (rostral) and ventral (caudal) parts of the lateral
ventricle, and both the thalamic and hippocampal ventricu-
lar walls near the ependyma (Figure 8A Through 8C). Lipid
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Figure 3. Atherosclerotic burden is reduced after treatment with an IL-1β antibody. Atherosclerosis was assessed by Oil Red O staining of
whole aortae and histology of lesions at aortic roots. Inset (A through D), Representative histology from Paigen diet–fed mice. Whole aortae in A
(control antibody) and B (IL-1β antibody), with en face Oil Red O staining; aortic root in C (control antibody) and D (IL-1β antibody), with Millers’
elastic van Gieson staining. Reduction in percent coverage of lesions in aortae from ApoE−/− mice fed a Western (E) and Paigen diet (F) with and
without antibody treatment (both *P<0.05). Aortic root lesion size in mice fed a Western (G) and Paigen (H) diet (*P<0.05) when treated with an
IL-1β antibody. Body weight changes in mice fed a Western (I) or Paigen (J) diet over the course of the study. Scale bars: 0.5 mm (A and B) and
50 μm (C and D). n=7–8 for E and G; n=11–13 for F and H.
deposition was frequently seen on the wall of larger ventricle-
associated blood vessels (Figure 8D) and occasionally in small
parenchymal arteries. Lipid droplets were found inside choroid
plexus cells (Figure 8F) and in the subfornical organ, associ-
ated with the accumulation of CD45-positive cells. Anti–IL-1β
antibody greatly reduced CD45-positive cells with leukocyte
and microglial morphology in the caudal lateral ventricle
(Figure 8A) but had no effect on lipid accumulation. Lipid depo-
sition and inflammation were far less pronounced in the brains
of mice fed a Western diet. Lipid droplets in the ependymal
wall of the third ventricle were seen in mice fed both Paigen
and Western diets (Figure 8F).
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Figure 4. IL-1β neutralization has secondary antiinflammatory effects in peripheral organs. Cytometric Bead Array was used to measure the
cytokine and chemokine levels in homogenized livers and spleen samples. IL-1α was significantly reduced in livers of ApoE−/− mice fed a
Paigen diet and the spleens of mice fed a Western diet. The chemokine CCL2 was reduced in the livers of ApoE−/− mice fed a Paigen diet. The
concentrations of interleukin-6 and CXCL1 were significantly reduced in response to IL-1β neutralization in mice fed a Western diet. Error bars
represent standard error, *P<0.05, **P<0.01 and ***P<0.001 vs ApoE−/− mice treated with a control antibody (n=6–12).
Discussion
We show that central nervous system inflammatory pathology
is associated with the development of atherosclerosis in high-
fat diet–fed ApoE−/− mice and, through genetic deletion of
IL-1R1 or neutralization of IL-1β, provide evidence that this is
mediated by IL-1. These findings identify IL-1 as a key driver in
the development of cerebrovascular inflammation in response
to atherogenic diet and systemic vascular disease.
Neutralization of IL-1β had antiinflammatory effects in pe-
ripheral organs. High-fat feeding increases hepatic inflamma-
tion, presumably because of an increased accumulation of
cholesterol.19 Treatment of hepatic cells with IL-1β also raises
the level of cholesterol uptake and accumulation.20 Therefore,
the reduced hepatic inflammation seen in the present study
could be due to the decreased availability of IL-1β to the hep-
atic cells and thus a decreased uptake of cholesterol.
Treatment with an anti–IL-1β antibody attenuated brain
leukocyte accumulation in ApoE−/− mice in the lateral ven-
tricle, but this effect was confined to the ventral ventricular
region in mice fed the less aggressive Western diet,21 with
the latter showing a much lower brain leukocyte invasion than
Paigen diet–fed animals. Vascular activation was reduced by
neutralization of IL-1β in mice fed a Western diet, but only a
trend toward reduction was seen in Paigen diet–fed animals
(which had much higher number of VCAM-positive blood ves-
sels), and no effect was seen on microglial activation in mice
fed either diet. These observations are not fully consistent with
the findings in ApoE−/−/IL-R1−/− mice fed a Paigen diet and
may be because of limited brain penetration of the anti-IL-1β
antibody, or because IL-1α, which can also mediate activation
of IL-1R1, contributes to changes in the brain and cerebrovas-
culature.
ApoE−/− mice fed either aWestern or Paigen diet are known
to develop atheroma throughout the aorta.22 Treatment with
an anti–IL-1β antibody caused a significant reduction in the
atherosclerotic lesion area in the descending aorta in mice
fed both a Paigen and Western diet and in the aortic root
in mice fed a Paigen diet. These data are consistent with a
recent study that reported similar effectiveness of another
anti–IL-1β antibody treatment for atherosclerosis.15 Because
ApoE−/−/IL-1R1−/− mice fed an atherosclerotic diet also de-
velop reduced peripheral pathology,14 it is not possible from
the findings of this study to determine the specific site of IL-1
action in driving central nervous system pathology. Reversal
DOI: 10.1161/JAHA.112.002006 Journal of the American Heart Association 7
IL-1 Drives Brain Inflammation in Atherosclerosis Denes et al
O
R
IG
IN
A
L
 R
E
S
E
A
R
C
H
Figure 5. Levels of microglial activation differed between ApoE−/− mice fed a Paigen or Western diet. Levels of microglial activation were
assessed through the immunostaining of Iba1. Microglial activation was assessed throughout the striatum, and the location of images shown is
indicated in the schematic diagram. Levels of microglial activation differed for each diet, but IL-1β neutralization had no effect. Error bars indicate
standard error (n=7), scale bars 200 μm and 10 μm.
Figure 6. IL-1β neutralization reduces vascular activation in ApoE−/− mice fed a Western diet.
Levels of vascular activation were assessed with immunostaining for the adhesion molecule
VCAM. Vascular activation was assessed throughout the cerebral cortex; locations of images
shown are indicated in the schematic diagram. Vascular activation was significantly reduced
in ApoE−/− mice fed a Western diet compared to those fed a Paigen diet. IL-1β neutralization
caused a significant reduction in vascular activation in ApoE−/− mice fed a Western diet. Error
bars indicate standard error, *P<0.05 vs ApoE−/− fed a Western diet (n=7). Scale bars 200 μm
and 50 μm.
of the effects of high-fat diet in mice lacking the IL-1 recep-
tor may be due to the absence of IL-1 signaling within the
cerebral vasculature or in the brain or may be secondary to
the amelioration of peripheral pathology. The fact that there
was no diet-dependent difference in atherosclerotic lesion
size but Paigen diet induced more substantial cerebrovascular
inflammation than did Western diet argues for some brain-
specific effects of IL-1 in response
to atherogenic diet and systemic
vascular inflammation. Regardless of
the site of IL-1 action, these data
show benefits of IL-1 blockade on
multiple tissues, notably the brain.
Central nervous system inflam-
mation is observed in response to
peripheral disease and may itself con-
tribute to the development of vascular
diseases. Recent experimental data
indicate a role for centrally mediated
signaling by inflammatory cytokines
such as IL-1β and tumor necrosis
factor-α in neurogenic hypertension or
metabolic disease.23–25 Neutralization
of IL-1β reversed weight loss in mice
fed a Paigen diet, and the decline in
voluntary physical activity in ApoE−/−
mice was also reversed by genetic
deletion of the IL-1 receptor. Central
IL-1–mediated effects on weight loss
might be important in light of recent
data that implicated inflammation-
induced central IL-1 signaling in muscle atrophy, which was
found to be dependent on the hypothalamic–pituitary–adrenal
axis.26 Paigen diet induces more substantial proinflammatory
changes than does the Western diet, which was also indi-
cated by the higher levels of CD45-positive cells in the lateral
ventricle and the reduction of body weight, as opposed to
the body weight increase seen in Western diet–fed mice. The
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Figure 7. Leukocytes accumulate in the choroid plexus of the lateral ventricle in ApoE−/− mice fed a Paigen diet and, to a lesser extent, a Western
diet, which is attenuated in the Paigen diet–fed mice by an anti–IL-1β antibody. A, CD45-positive leukocytes accumulate in the ventral, caudal
part of the lateral ventricle in ApoE−/− mice fed a Paigen diet, which is attenuated by IL-1β antibody treatment. B, Accumulation of leukocytes
in this region is not seen in mice fed a Western diet. C, CD45-positive leukocytes accumulate in the choroid plexus of the lateral ventricle in
ApoE−/− mice fed a Paigen diet, which is attenuated by IL-1β antibody treatment. Data in C were not normally distributed; therefore in addition to
unpaired t test (P=0.013), nonparametric Mann-Whitney test (P=0.0041) was also performed. D, Fewer CD45-positive cells accumulated in this
region in mice fed a Western diet, but IL-1β antibody treatment had no significant effect. Schematic diagram indicates the location of images. E
and F, Quantification of the total number of CD45-positive leukocytes in mice fed a Paigen (E) or Western (F) diet. Error bars represent standard
error, *P<0.05 vs ApoE−/− mice treated with a control antibody (n=7).
different mechanisms of action of Paigen and Western
diets21,22 and, therefore, the different levels of systemic and
central inflammation induced might also explain differences
seen in the effect of IL-1β neutralization on the various inflam-
matory parameters we studied in the brain.
Lipid deposition in ventricle-associated blood vessels,
choroid plexus, circumventricular organs, and ventricles indi-
cates pronounced vascular effects elicited by an atherogenic
diet in the brains of mice fed a Paigen diet. Lipid accumula-
tion appeared to take place independently from IL-1β. How-
ever, recruitment of inflammatory cells was localized to lipid
accumulation in the brain and was markedly reduced in re-
sponse to IL-1β neutralization, which suggests that local lipid
deposition–induced stimuli might be directly involved in inflam-
matory cellular responses in the brain. Collectively, our data
suggest that interventions against central and systemic effects
of vascular diseases could have therapeutic potential. Elevated
systemic inflammatory burden is considered a high risk for car-
diovascular and cerebrovascular diseases.27–29 Clear associa-
tion exists between depression and cardiovascular/metabolic
disease,30–32 and IL-1 signaling has been linked closely with
the development of decreased motivational disorders such as
depression.33–35
Therefore, patients with multiple risk factors for heart dis-
ease or stroke might benefit from neutralization of systemic
IL-1β activity. Similarly, the potential effects of high-fat diet
and atherosclerosis on cognitive decline and depression might
be reduced by interventions against IL-1 signaling.
Conclusions
We present evidence that the cytokine IL-1 contributes to
neuroinflammatory changes in mice developing diet-induced
atherosclerosis. IL-1β blockade provides a potential therapeu-
tic opportunity to limit atherosclerosis, associated neuroin-
flammation, and hence cerebrovascular disease such as stroke
and vascular dementia.
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